Financial Performance - The company's operating revenue for Q1 2024 was CNY 426,063,885, a decrease of 15.45% compared to CNY 503,909,819 in Q1 2023[17] - Net profit attributable to shareholders for Q1 2024 was CNY 31,199,061, down 51.81% from CNY 64,744,366 in the same period last year[17] - Total operating revenue for Q1 2024 was CNY 426,063,885, a decrease of 15.4% compared to CNY 503,909,819.72 in the same period last year[44] - The net profit for the current period is ¥31,199,061.62, a decrease of 51.8% compared to ¥64,744,366.06 in the previous period[45] - The total profit for the current period is ¥35,078,651.58, down from ¥75,764,451.63, reflecting a decline of 53.7%[45] - Basic earnings per share for the current period is ¥0.0780, down from ¥0.1793 in the previous period, representing a decrease of 56.5%[45] - The total comprehensive income for the current period is ¥31,199,061.62, a decrease of 51.8% from ¥64,744,366.06 in the previous period[45] Cash Flow - The net cash flow from operating activities was negative CNY 89,497,667, a significant decline of 723.06% compared to a positive CNY 14,364,159 in Q1 2023[17] - Cash flow from operating activities shows a net outflow of ¥89,497,667.93, compared to a net inflow of ¥14,364,159.31 in the previous period[47] - Net cash flow from investing activities improved to ¥257,209,140.88, contrasting with -¥127,613,912.35 in the previous year, marking a 301.55% change[36] - Cash inflow from investment activities is ¥1,346,719,951.55, significantly higher than ¥220,801.68 in the previous period[47] - The cash outflow for investment activities is ¥1,089,510,810.67, compared to ¥127,834,714.03 in the previous period, indicating a substantial increase in investment spending[47] Assets and Liabilities - Total assets as of March 31, 2024, were CNY 5,640,263,227, a slight decrease of 0.19% from CNY 5,650,770,791 at the end of 2023[17] - Total liabilities decreased to CNY 1,247,752,907.64 from CNY 1,290,933,355.79, indicating improved financial stability[42] - Total liabilities and equity amounted to ¥5,640,263,227.01, down from ¥5,650,770,791.34[28] - Other current assets decreased by 88.36% to CNY 40,088,322 from CNY 344,331,949, primarily due to the maturity of time deposits[8] Research and Development - R&D expenses increased by 45.49% to CNY 15,176,270 from CNY 10,431,275 in Q1 2023, reflecting higher costs for commissioned development and material consumption[8] - Research and development expenses increased to CNY 15,176,270.87, representing a rise of 45.3% compared to CNY 10,431,275.48 in the previous year[44] - The company plans to continue focusing on R&D to drive future growth despite current revenue challenges[44] Shareholder Information - The company had a total of 35,027 common shareholders at the end of the reporting period[36] - The largest shareholder, Yan Xiaohui, holds 22.15% of the shares, totaling 88,585,200 shares[36] Tax and Other Expenses - The company reported a 64.80% decrease in income tax expenses, totaling ¥3,879,589.96, down from ¥11,020,085.57[36] - Operating income from non-operating activities increased by 100.91% to ¥54,045.78, up from ¥26,900.00[36] Market Outlook - The overall market outlook remains cautious due to the decline in revenue and increased operational costs, necessitating strategic adjustments[44] - The company did not report any non-recurring gains or losses for the period[6] Accounting Standards - The company has initiated the first-time implementation of new accounting standards starting in 2024, which may impact future financial reporting[49]
宏源药业(301246) - 2024 Q1 - 季度财报